.svg)
According to the 2026 review, Pharmaceutical Drug Lifecycle: A Comprehensive Scientific Review of Research and Development Phases, Attrition Rates, and Global Disparities, by Gustavo Lorenzo Moretta, only about 9.6–21.5% of compounds entering clinical trials ultimately gain regulatory approval. Pharmaceutical product development therefore carries significant attrition, but the challenge is not only progressing a candidate through successive development stages. Decisions made early around the intended product profile, material attributes and process parameters can determine how effectively a formulation performs, scales and transfers into commercial manufacturing.
A Target Product Profile (TPP) provides that direction early, while Critical Material Attributes (CMAs), Critical Process Parameters (CPPs), and Quality by Design (QbD) help translate product expectations into formulation and process decisions that can hold up as development advances.
The following stages show how these considerations shape successful pharmaceutical product development from early product definition through commercial manufacturing.
Development starts by defining the intended product rather than immediately selecting excipients or manufacturing processes.
A TPP establishes parameters such as therapeutic indication, patient population, route of administration, dosage form, dose strength, release profile and expected shelf life. It gives formulation, manufacturing, clinical, and regulatory teams a common development objective.
The API must then be characterised against that objective. Solubility and permeability indicate potential absorption constraints; stability studies identify degradation risks; particle size, morphology and polymorphic form can influence processing and product performance; and the required dose affects whether the intended dosage form is practical.
Identifying these constraints early can change the development path. A poorly soluble API, for example, may require particle engineering, a solid dispersion, or another enabling approach. Early decisions can also indicate what capabilities will eventually be required from the pharmaceutical manufacturer.
Once the product requirements and API risks are understood, preformulation work determines how those properties translate into a practical dosage form.
API-excipient compatibility, solid-state behaviour, solubility, stability and powder characteristics guide excipient and process selection. The formulation strategy then needs to address the specific development challenge, whether that is poor bioavailability, instability, an unacceptable taste profile or a modified-release requirement.
Prototype development is important because a technically plausible formulation is not necessarily a viable product. Candidate formulations can be compared using dissolution, content uniformity, stability, and early manufacturability data before the development team commits to one approach.
Formulation decisions also extend beyond technical performance. Patient needs, risk-benefit considerations, and responsible product design remain relevant throughout development, as discussed further in The Ethical Considerations of Pharmaceutical Product Development.
A successful laboratory formulation still needs to become a controlled manufacturing process.
At this stage, developers determine which material and process variables have the greatest influence on finished-product quality. Critical Material Attributes (CMAs) may include API particle size, polymorphic form or excipient characteristics, while Critical Process Parameters (CPPs) can include mixing time, granulation conditions, drying temperature or compression force.
A QbD approach connects these variables to the product's Critical Quality Attributes (CQAs). Risk assessment and experimental studies can then establish appropriate operating ranges and controls.
This work matters because manufacturability should be demonstrated before commercial scale-up. A formulation that performs well only under tightly controlled laboratory conditions can create significant problems when equipment, batch size and material variability change.
Scale-up is not simply a larger version of a laboratory batch. Increasing batch size can change mixing, heat and mass transfer, drying, compression and other process behaviours.
Pilot and engineering batches help determine whether the established process controls remain appropriate at larger scale. The resulting knowledge must then be transferred from R&D to the pharmaceutical product manufacturer through defined manufacturing instructions, specifications, analytical methods, process parameters and risk assessments.
At the same time, development teams generate the stability, analytical, validation and manufacturing evidence needed to demonstrate that the proposed commercial process can consistently deliver the predefined product quality.
Regulatory approval and process validation mark the transition into routine manufacturing, but they do not end pharmaceutical product development.
Commercial production requires qualified equipment, trained personnel, validated processes, and an established control strategy. Continued process verification then tracks attributes such as assay, impurities, dissolution and content uniformity to identify trends or process drift.
Changes are also inevitable over a product's commercial life. New equipment, manufacturing sites, suppliers, batch sizes or market requirements may require formal assessment and regulatory action.
This is where early development choices have long-term consequences. A robust formulation and scalable process can support more reliable supply and smoother manufacturing changes. Conversely, unnecessary process complexity or dependence on highly specialised equipment can increase cost and restrict manufacturing flexibility.
ZIM Laboratories Limited is a therapy-agnostic and innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
